25 Facts About Eva Feldman

Eva Feldman's was recently named the James W Albers Distinguished University Professor of Neurology.

Eva Feldman has made contributions to biomedical research and clinical care in many critical areas of neurodegenerative disease.

Eva Feldman's has conducted pioneering research on developing stem cell therapies to treat these diseases.

Eva Feldman's is annually listed in Best Doctors in America and is a member of the Association of American Physicians and National Academy of Medicine.

Eva Feldman's is a Fellow of the American Association for the Advancement of Science.

Related searches

Eva Feldman's has been continuously NIH funded since 1989 and has received numerous awards and honors throughout her remarkable career.

Dr Feldman then returned to the University of Michigan to complete a neuromuscular disorders fellowship, with longtime mentor Dr James Albers, and her career has since progressed to her current role as the Russell N DeJong Professor of Neurology and Director of both the NeuroNetwork for Emerging Therapies and ALS Center of Excellence.

In 1988, Eva Feldman became an assistant professor and opened her basic science laboratory in the Department of Neurology at Michigan Medicine, serving as member of the Neuroscience Program and Michigan Diabetes Research and Training Center.

In 2000, Feldman became Director of the Juvenile Diabetes Research Foundation Center for the Study of Complications in Diabetes, Director of the ALS Center of Excellence at Michigan Medicine, and a fully endowed professor, the Russell N DeJong Professor of Neurology.

Eva Feldman's was appointed the inaugural Director of the A Alfred Taubman Medical Research Institute in 2007, after U-M received a multimillion-dollar gift from A Alfred Taubman for its creation.

Eva Feldman is the author of more than 500 articles, 71 book chapters, and four books.

Eva Feldman leads multiple clinical trials focused on understanding and treating neurological disorders, with an emphasis on ALS and neuropathy.

Eva Feldman's was the first woman in 25 years to receive the Robert S Schwab Award from the American Clinical Neurophysiology Society.

Eva Feldman's is the only U-M alumnus to receive both Early and Distinguished Career Achievement Awards from the U-M Medical Alumni Society.

Eva Feldman's established an Emerging Scholars program to support promising early-career physician scientists at the Taubman Institute, which has provided unencumbered seed funding to over 20 junior investigators, with an emphasis on improving the diversity of the clinician-scientist workforce.

Dr Eva Feldman served as Director of the Taubman Institute for 10 years and had remarkable success in fulfilling the founder's vision.

The mission of Eva Feldman's research remains the same: to advance scientific discovery and establish therapies for neurological diseases.

Eva Feldman sees some of her greatest accomplishments as guiding and supporting the future of medical science through mentoring and inspiring the next generation of scientists and physicians.

Eva Feldman is renowned for her groundbreaking research in amyotrophic lateral sclerosis, an invariably fatal nerve affliction more commonly known as Lou Gehrig's disease.

Eva Feldman's has made national headlines for work uncovering links between ALS risk and pesticide exposures, and she and her team received a method-of-use patent in 2018 to repurpose a family of drugs, the Jakinibs, for use in ALS treatment based on her data identifying a novel mechanism by which the immune system contributes to disease progression.

Dr Eva Feldman founded the University of Michigan ALS Consortium, establishing a biorepository for ALS, which has facilitated identification of epigenetic, transcriptomic, metabolomic, and immunological unique signatures in ALS along with potential biomarkers.

Eva Feldman is equally known internationally for her work in diabetes complications, particularly peripheral neuropathy.

Eva Feldman's has uncovered important roles for lipids and the metabolic syndrome in neuropathy pathogenesis in prediabetes and type 2 diabetes and is an author on the American Diabetes Association Guidelines on the treatment of diabetic neuropathy.

Eva Feldman's is currently developing risk assessment tools to inform the care of COVID-19 patients with type 2 diabetes during this health crisis as well as pandemics to come, while studying the neurological implications of patients with Long COVID.

Dr Eva Feldman is leading efforts to understand how metabolic dysfunction drives neurologic complications and impacts brain health.

Related searches